Clinical Trials Logo

Clinical Trial Summary

The main objective of this study is to evaluate the systemic impact of salting out of trace elements (TE) by metallic and nonmetallic implantable medical devices (IMD) and in particular the immune response of the organism to these trace elements and of their target organs, and to identify circulating protein biomarkers which might indicate an evolution of inflammation caused by an IMD.


Clinical Trial Description

As secondary objectives, the study aims: - to establish the norms of concentrations of free TE and nanoparticles for some forty of elements (in particular Chrome, Cobalt, Nickel, Titanium, Tantalum, Zirconium, Tungsten, Gold, Silver, Mercury, Molybdenum, Strontium ...) in different materials (blood, urine, hair and the viscera), with non-IMD holder subjects, before and after mineralization of these materials (dead patients and autopsied non-IMD holder subjects and subjects before placement of IMD. - to evaluate the distribution of concentrations of metals in the same materials and in peri-prothetic environment with IMD holder subjects (dead autopsied patients), more often with no inflammatory sign, with possibility of some probably inflammatory IMD. - to evaluate the parameters of distributions of concentrations of metals in same materials (with the exception of the viscera) with living IMD holder patients, with inflammatory reaction (during revision surgery). - to define the most suitable material (accessibility, concentrations, absence of contamination) for follow-up and evolution of inflammation in order to determinate norms of studied metals concentration. - to determinate proportion between different forms of circulation: particulate form (analysis after full mineralization) or free form (analysis without mineralization, permitting measurement of free forms), trace elements in organism. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03812627
Study type Interventional
Source Assistance Publique - Hôpitaux de Paris
Contact
Status Completed
Phase N/A
Start date June 24, 2019
Completion date March 19, 2021

See also
  Status Clinical Trial Phase
Recruiting NCT03219593 - Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric Cancer Phase 2
Active, not recruiting NCT04681040 - Risk Stratification of COVID-19 Using Urine Biomarkers
Recruiting NCT05372172 - Tennessee Alzheimer's Project
Recruiting NCT06096766 - the Correlation Between Ovarian Function and Serum Biomarkers
Completed NCT04103632 - Screening and Diagnosing Exercise-induced Bronchoconstriction in Recreational Young Athletes (12-18 y) N/A
Completed NCT01159730 - Study to Assess the Safety and Efficacy of Multiple Doses of VB-201 on Biomarkers Phase 2
Completed NCT04507724 - The Use of Biochemical Analyzes to Monitor the Development of Wounds
Completed NCT06338111 - Can we Improve Mortality Prediction in Patients With Sepsis in the Emergency Department
Active, not recruiting NCT05027165 - Prospective Evaluation of Immunological, Molecular-genetic, Image-based and Microbial Analyzes to Characterize Tumor Response and Control in Patients With Inoperable Stage III NSCLC Treated With Chemoradiotherapy Followed by Consolidation Therapy With Durvalumab
Not yet recruiting NCT02931136 - Early Diagnosis and Early Treatment of Alzheimer's Disease Based on Senile Plaque Imaging Phase 4
Not yet recruiting NCT03739892 - Biomarkers to Predict Gain From Therapy in Motor Stroke N/A
Recruiting NCT03801681 - ARrhythmias in MYocarditis
Recruiting NCT05372965 - The Effects of Smoking on miRNA-223 Before-After Non-Surgical Periodontal Therapy in Patients With Stage-3, Grade-B Periodontitis N/A
Completed NCT04772495 - miRNA Biomarkers in Multiple Sclerosis
Active, not recruiting NCT06178692 - Validation Study of a Serum-miRNA Signature in Glioma Patients.
Recruiting NCT04931537 - Screening and Application Research of Early Diabetic Nephropathy Markers Based on Lipidomics.
Recruiting NCT05090410 - Efficacy and Safety of Selective JAK 1 Inhibitor Filgotinib in Active Rheumatoid Arthritis Patients With Inadequate Response to Methotrexate Phase 3
Not yet recruiting NCT05764356 - Imapct of bioMarkers on Pharmacodynamics and Bleeding Risk of Direct Oral AntiCoagulants and Ticagrelor Study II
Recruiting NCT02201446 - The Role of Circulating Soluble CD74 in Acute Lung Injury N/A
Not yet recruiting NCT05752890 - A Novel Biomarker for Response and Prognosis of HBV-related Hepatocellular Carcinoma